NCT07426107Not yet recruiting
Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization
An Artificial Intelligence-Enhanced Longitudinal Cohort Study to Optimize Revascularization Decisions in Patients With Coronary Artery Disease and Immune Thrombocytopenia (The ITP-CAD AI-REVASC Study)
Source: ClinicalTrials.gov · Last updated 23 Feb 2026
Brief summary (registry, in English)
This study employs a dual-cohort design to develop and validate a prognostic model for Major Adverse Cardiovascular Events (MACE) following revascularization in immune thrombocytopenia (ITP) patients with Coronary Artery Disease (CAD). The model will be developed and trained using a retrospective multi-center cohort (development/training cohort). Its performance will then be prospectively validated in a separate, consecutively enrolled prospective cohort (validation cohort). The goal is to create an AI-based tool to assist in personalized risk assessment and decision-making for this high-risk population.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 17 Dec 2025
- Start date
- 25 Feb 2026
- Primary completion date
- 25 Feb 2028
- Lead sponsor
- Xiao Hui Zhang
- Diseases
- Coronary artery disease
- NCT number
- NCT07426107
What you commit to
- Study type: Observational
- Planned participants: 600
- From 25 Feb 2026 to the primary completion date, 25 Feb 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A history of Type 2 Myocardial Infarction prior to the index treatment decision.
Other illness
- Secondary causes of thrombocytopenia (e.g., drug-induced, hematologic malignancy, hypersplenism, liver disease).
- Conditions requiring long-term therapeutic anticoagulation (e.g., atrial fibrillation, mechanical heart valve).
- Life expectancy less than 1 year due to non-cardiovascular disease.
Other
- Inability to comply with follow-up.
- Inability to give informed consent.
- Pregnancy or breastfeeding.
Who the study is looking for
- Age ≥ 18 years.
- Diagnosis of primary Immune Thrombocytopenia (ITP) according to international working group criteria.
- Diagnosis of Coronary Artery Disease (stable angina or Acute Coronary Syndrome) confirmed by coronary angiography.
- The diagnosis of ITP must be established and documented prior to the diagnosis of CAD.
- Capable of providing informed consent (for prospective enrollment and data collection).
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.